Our client was launching a novel therapy for the treatment of Ulcerative Colitis (UC) and wanted to assess the strategic potential of patient affordability solutions across 13 international markets

The client had developed and launched a human papillomavirus (HPV) vaccine which was reimbursed for adolescents through national immunization programs for only some markets

The client developed an innovative treatment for sickle cell disease (SCD) and wanted to assess the payer and self-pay landscape, understand barriers to funding / purchase decisions, and identify affordability solutions to support access to Product X across markets in-scope

The application of biomarkers in therapy areas beyond oncology will likely play an ever-crucial role in developing more targeted therapies in high unmet need indications, while providing payers with new attributes by which to assess a new treatment’s value.

A global pharmaceutical company was developing a new product for the treatment of Parkinson’s disease; the product had a novel mechanism of action and was in early phase of clinical development

A biopharmaceutical company was developing the first gene therapy for a rare disease. It was expected to be a one-time therapy that would replace the current chronic standard of care.

A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines.